Skip to main content

Tweets

Here's a meta-analysis of MACE/malignancy in JAKi vs TNFi in observational cohort studies. All the epidemiological challenges here aside, it's a good reminder that with ORAL Surveillance it's *cardiovascular risk enriched pts* we're concerned about. #ACR24 ABST2264 @RheumNow https://t.co/vIXlrI3V2d
David Liew @drdavidliew ( View Tweet )
1 week 1 day ago
Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA. -Pts with nail involvement treated with IXE or ADA had higher SJC and TJC improvement vs those without involvement at W12, W24 and W52. -IXE achieved rapid response for DAPSA-LDA as… https://t.co/SR36qCthQo https://t.co/hI3tD5hATJ
Adela Castro @AdelaCastro222 ( View Tweet )
1 week 1 day ago
3D management of Sscl from @delgaldoFrances -Time -Severity -Type of organ involvement *Identify phenotypes: fibrotic vs vascular damage. *Raynaud’s red flags: +ANA, puffy fingers, abn capillaroscopy. *Early ttnt of of digital ulcers delays onset of PAH. *High IFN-I =marker of… https://t.co/ByfuV0MJds https://t.co/GdRVwuRf4E
Adela Castro @AdelaCastro222 ( View Tweet )
1 week 1 day ago
My ramblings on the SELECT-GCA study and predictions of the place of upadacitinib in clinical practice in GCA are up now on RheumNow #ACR24 @RheumNow https://t.co/DR5VgVmdse

Richard Conway @RichardPAConway ( View Tweet )

1 week 1 day ago
I've shared some further thoughts on @jeffsparks SAIL-RA study and its finding of the strong association of RA-ILD with disease activity in early RA. And of course couldn't resist going on a tangent about the ACR ILD guidelines! #ACR24 @RheumNow https://t.co/UUDbWw38Im

Richard Conway @RichardPAConway ( View Tweet )

1 week 1 day ago
A key practice changing study (I hope) from #ACR24 has been the preCARA study. Fertility increases with aggressive disease control. My video on this study is up now on @RheumNow https://t.co/Pf3rdTHbOJ

Richard Conway @RichardPAConway ( View Tweet )

1 week 1 day ago
The TAPIR study presented at #ACR24 may not be as attention grabbing as others like SELECT-GCA, but in my opinion it is arguablyone of the most important ANCA-vasculitis studies ever. I've shared some further thoughs in an article on @RheumNow https://t.co/mImAE8ezSQ

Richard Conway @RichardPAConway ( View Tweet )

1 week 1 day ago
RheumNow Day 2 Recap: ACR Convergence 2024 Highlights https://t.co/YAwOEaNsWs

Dr. John Cush @RheumNow ( View Tweet )

1 week 1 day ago
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush @RheumNow ( View Tweet )

1 week 1 day ago
We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
1 week 1 day ago

VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
1 week 1 day ago
To stop tsDMARD / bDMARD To improve #COVIDVACCINE response in those w several previous #COVID19 #vaccinations is NOT necessary This will change my practice! #ACR24 @RheumNow @ACRheum https://t.co/WXeqMOEfuA

Janet Pope @Janetbirdope ( View Tweet )

1 week 1 day ago